Could These 3 Potential Blockbusters Transform Biogen?
Biogen's (NASDAQ: BIIB) earnings report last week offered us a clear picture of why the biotech company is in need of a change. Its main multiple sclerosis (MS) business is on the decline as blockbuster Tecfidera loses ground to generic competition -- and newer MS drug Vumerity is taking a while to generate significant revenue. Sales of other big drugs also are on the decline.
But there may be brighter days ahead for Biogen. CEO Michel Vounatsos says the company is in the process of becoming not just an MS company -- but a full neuroscience company. Let's take a look at three drugs with blockbuster potential and see if they can indeed transform this biotech giant.
Image source: Getty Images.
Source Fool.com
